BioMarin Pharmaceutical

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: BioMarin releases positive study data for hemophilia gene therapy

Pharmalot Ed Silverman

FDA rejects drug for Duchenne muscular dystrophy

Pharmalot Ed Silverman

FDA panel casts doubt on Duchenne drug

Pharmalot Ed Silverman

FDA review casts doubt on first drug for combating Duchenne